Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Ken W who wrote (2969)	9/8/2003 1:32:59 PM
From: Sergio H	Read Replies (1) \| Respond to of 23958

Guys, IDEV is signalling that news is coming up. Marketing agreement is expected. WR Hambrecht analyst is seconding JoeinIowa's valuation opinion on Mike's MDCO, which is "IN PLAY." <9:16AM The Medicines Co downgraded at WR Hambrecht (MDCO) 29.81: WR Hambrecht downgrades to Hold from Buy based on the stock's premium valuation (10.1x their 2004 rev est vs the biotech avg of about 8x) ahead of expected good clinical data at the upcoming TCT meeting; even though firm continues to believe that MDCO will report continued non-inferiority to heparin in the 6-month data from the Phase III REPLACE-2 trial, they do not expect the data to translate immediately into explosive sales growth; raises target to $32 from $25.> Again, several new highs in our folio. Small caps are red hot: <Russell 2000 explores record territory The Russell 2000 index, which measures the performance of 2,000 of the smallest companies in its companion Russell 3000 index, is also exploring record territory. It closed at 530 on Thursday, its highest level in the past two years and within striking distance of its all-time high of 606, set in March 2000. Tom Warburton, a research analyst at Frank Russell Co., said the biggest performers in the Russell 2000 this year have been technology and health care stocks -- both up more than 40 percent. Within the technology segment, chip stocks and cyclical tech stocks are shining. Within health care, it's been biotech. The overall gains are being driven by the smallest of the small caps, made up of firms with market capitalization of less than $300 million. "Those stocks have less liquidity, so they go up more when money comes back into the market," he said. "The bottom half (in market cap) has really driven the performance."> marketwatch.com